CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study

Acta Neuropathologica

Volumn 131, Issue 6, 2016, Pages 935-949

  Kang, Ju Hee ^a,b   Mollenhauer, Brit ^c,d   Coffey, Christopher S ^e   Toledo, Jon B ^a   Weintraub, Daniel ^a,f   Galasko, Douglas R ^g   Irwin, David J ^a   Van Deerlin, Vivianna ^a   Chen Plotkin, Alice S ^a   Caspell Garcia, Chelsea ^e   Waligórska, Teresa ^a   Taylor, Peggy ^h   Shah, Nirali ^a   Pan, Sarah ^a   Zero, Pawel ^a   Frasier, Mark ⁱ   Marek, Kenneth ^j   Kieburtz, Karl ^k   Jennings, Danna ^j   Tanner, Caroline M ^l   Simuni, Tanya ^m   Singleton, Andrew ⁿ   Toga, Arthur W ^o   Chowdhury, Sohini ⁱ   Trojanowski, John Q ^a   Shaw, Leslie M ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Inha University School of Medicine   (South Korea)

^c PARACELSUS ELENA KLINIK   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e UNIVERSITY OF IOWA   (United States)

^f DEPARTMENT OF VETERANS AFFAIRS   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BIOLEGEND   (United States)

ⁱ THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^j INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^k UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^l SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ NATIONAL INSTITUTE ON AGING   (United States)

^o UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

Alpha synuclein; A 1 42; Cerebrospinal fluid biomarker; Parkinson s disease; Parkinson s Progression Markers Initiative; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; QUANTITATIVE ANALYSIS; COGNITION; COGNITION DISORDERS; COMPLICATION; DISEASE COURSE; EARLY DIAGNOSIS; GENETICS; MIDDLE AGED; PHENOTYPE; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITION; COGNITION DISORDERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHENOTYPE; PROSPECTIVE STUDIES;

EID: 84961613805     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1552-2     Document Type: Article

References (43)

1. Aarsland D, Andersen K, Larsen JP et al (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392
2. Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289:18–22
3. Alves G, Larsen JP, Emre M et al (2006) Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord 21:1123–1130
4. Alves G, Brønnick K, Aarsland D et al (2010) CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81:1080–1086
5. Alves G, Lange J, Blennow K et al (2014) CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology 82:1784–1790
6. Compta Y, Parkkinen L, O’Sullivan SS et al (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134:1493–1505
7. Duka T, Duka V, Joyce JN, Sidhu A (2009) α-Synuclein contributes to GSK-3β-catalyzed tau phosphorylation in Parkinson’s disease model. FASEB J 23:2820–2830
8. Giasson BI, Forman MS, Higuchi M et al (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636–640
9. Gomperts SN, Locascio JJ, Rentz D et al (2013) Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80:85–91
10. Guo JL, Covell DJ, Daniels JP et al (2013) Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 154:103–117
11. Halliday GM, Holton JL, Revesz T, Dickson DW (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122:187–204
12. Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 19:1043–1049
13. Hughes TA, Ross HF, Musa S et al (2000) A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 54:1596–1602
14. Irwin DJ, White MT, Toledo JB et al (2012) Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72:587–598
15. Irwin DJ, Lee VM, Trojanowski JQ (2013) Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci 14:626–636
16. Jankovic J, McDermott M, Carter J et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. Neurology 40:1529–1534
17. Jellinger KA (1999) Post mortem studies in Parkinson’s disease-is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 56:1–29
18. Kang JH, Irwin DJ, Chen-Plotkin AS et al (2013) Association of cerebrospinal fluid β-amyloid 1-42, t-tau, p-tau181, and α-synuclein levels with clinical features of drug-naïve patients with early Parkinson disease. JAMA Neurol 70:1277–1287
19. Levy G, Tang MX, Louis ED et al (2002) The association of incident dementia with mortality in PD. Neurology 59:1708–1713
20. Lewis SJG, Foltynie T, Blackwell AD et al (2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76:343–348
21. Mata IF, Leverenz JB, Weintraub D et al (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405–1412
22. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W et al (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10:230–240
23. Montine TJ, Shi M, Quinn JF et al (2010) CSF Aβ42 and tau in Parkinson’s disease with cognitive impairment. Mov Disord 25:2682–2685
24. Nalls MA, Pankratz N, Lill CM et al (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 46:989–993
25. Parashos SA, Swearingen CJ, Biglan KM et al (2009) Determinants of the timing of symptomatic treatment in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol 66:1099–1104
26. Parashos SA, Luo S, Biglan KM et al (2014) Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. JAMA Neurol 71:710–716
27. Initiative Parkinson Progression Marker (2011) The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95:629–635
28. Parnetti L, Tiraboschi P, Lanari A et al (2008) Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64:850–855
29. Parnetti L, Chiasserini D, Bellomo G et al (2011) Cerebrospinal fluid tau/α-synuclein ratio in Parkinson’s disease and degenerative dementia. Mov Disord 8:1428–1435
30. Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50:743–755
31. Rajput AH, Sitte HH, Rajput A et al (2008) Globus pallidus dopamine and Parkinson motor subtype: clinical and brain biochemical correlation. Neurology 70:1403–1410
32. Rajput AH, Voll A, Rajput ML et al (2009) Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 73:206–212
33. Selikhova M, Williams DR, Kempster PA et al (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132:2947–2957
34. Shi M, Bradner J, Hancock AM et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570–580
35. Siderowf A, Xie SX, Hurtig H et al (2010) CSF amyloid β1-42 predicts cognitive decline in Parkinson disease. Neurology 75:1055–1061
36. Stebbins GT, Goetz CG, Burn DJ et al (2013) How to identify tremor dominant and postural instability/gait difficulty groups with the Movement Disorder Society Unified Parkinson’s Disease Rating Scale: comparison with the Unified Parkinson’s Disease Rating Scale. Mov Disord 28:668–670
37. Toledo JB, Korff A, Shaw LM et al (2013) CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease. Acta Neuropathol 126:683–697
38. Toledo JB, Gopal P, Raible K et al (2015) Pathological a-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology. Acta Neuropathol (E-pub)
39. Tsuang D, Leverenz JB, Lopez OL et al (2013) APOE e4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70:223–228
40. van de Berg WD, Hepp DH, Dijkstra AA et al (2012) Patterns of α-synuclein pathology in incidental cases and clinical subtypes of Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S28–S30
41. Williams-Gray CH, Foltynie T, Brayne CEG et al (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798
42. Williams-Gray CH, Goris A, Saiki M et al (2009) Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J Neurol 256:493–498
43. Wills J, Jones J, Haggerty T et al (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol 225:210–218